CVS · Earnings call · 2026Q2T · Full report
PBM Regulatory Risk
CVS HEALTH Corp · 2026-08-05 · Importance 47 · Surprise 60 · In source text
CVS expects recent legislation and regulatory developments, including its proposed settlement with the FTC, to accelerate Caremark's transition toward net-cost pricing models. Management said the transition is intended to preserve the value PBMs provide while increasing transparency at the pharmacy counter. The company is also taking a disciplined approach to client renewals and underwriting as industry dynamics affect legacy contracts and 2027 Caremark membership.
Key facts
- Caremark is transitioning toward pricing models grounded in lowest net cost and expects the transition to net cost price models to accelerate with recent legislation and regulatory developments, including the proposed settlement with the FTC.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| margin | unclear | contingent | — | Caremark is transitioning toward pricing models grounded in lowest net cost and expects the transition to net cost price models to… |